Terminated PHASE1 INTERVENTIONAL 6-arm NCT07039929

Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants

Sponsor: Incyte Corporation

Conditions Healthy Participants

Interventions INCB000631 Placebo

Updated 4 times since 2025 Last updated: Oct 27, 2025 Started: Jul 28, 2025 Primary completion: Oct 11, 2025 Completion: Oct 11, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategic Business Decision

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

Other Healthy Participants trials with similar outcome

Browse all Healthy Participants trials

This PHASE1 trial investigates Healthy Participants and is currently terminated or withdrawn. Incyte Corporation leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Nov 2025 — Present [monthly]

Terminated PHASE1

Status: Recruiting → Terminated
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE1
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jul 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation

Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lincoln, United States